P Bauermann1, A Heiligenhaus1,2, C Heinz1,2. 1. Department of Ophthalmology, St. Franziskus Hospital, Muenster, Germany. 2. Department of Ophthalmology, University of Duisburg-Essen, Essen, Germany.
Abstract
Purpose: To report a case of effective Janus kinase inhibitor treatment in a case of anterior uveitis complicated by macular edema in a patient with juvenile idiopathic arthritis.Case report: A 22-year-old woman suffering from JIA-associated anterior uveitis since the age of 2 years presented with recurrent active uveitis and macular edema in both eyes responding only to intraocular dexamethasone implants in the past while several other DMARD therapies including biologicals failed to control activity and edema. After starting treatment with tofacitinib 5 mg twice daily arthritis, uveitis, and macular edema were controlled without any further steroid implants. Conclusion: In this case, Janus kinase inhibitor represented a successful strategy for severe refractory uveitis and ME and therefore Janus kinase inhibitor may be an option in selected cases not responding properly to conventional synthetic and biologic DMARDs or to intraocular steroid implants.
Purpose: To report a case of effective Janus kinase inhibitor treatment in a case of anterior uveitis complicated by macular edema in a patient with juvenile idiopathic arthritis.Case report: A 22-year-old woman suffering from JIA-associated anterior uveitis since the age of 2 years presented with recurrent active uveitis and macular edema in both eyes responding only to intraocular dexamethasone implants in the past while several other DMARD therapies including biologicals failed to control activity and edema. After starting treatment with tofacitinib 5 mg twice daily arthritis, uveitis, and macular edema were controlled without any further steroid implants. Conclusion: In this case, Janus kinase inhibitor represented a successful strategy for severe refractory uveitis and ME and therefore Janus kinase inhibitor may be an option in selected cases not responding properly to conventional synthetic and biologic DMARDs or to intraocular steroid implants.
Authors: Hayley James; Grace L Paley; Richard Brasington; Philip L Custer; Todd P Margolis; Michael A Paley Journal: Am J Ophthalmol Case Rep Date: 2021-04-21
Authors: Carmen Álvarez-Reguera; Diana Prieto-Peña; Alba Herrero-Morant; Lara Sánchez-Bilbao; José Luis Martín-Varillas; Elena González-López; María Gutiérrez-Larrañaga; David San Segundo; Rosalía Demetrio-Pablo; Gonzalo Ocejo-Vinyals; Miguel A González-Gay; Ricardo Blanco Journal: Ther Adv Musculoskelet Dis Date: 2022-04-29 Impact factor: 3.625
Authors: Athimalaipet V Ramanan; Andrew D Dick; Catherine Guly; Andrew McKay; Ashley P Jones; Ben Hardwick; Richard W J Lee; Matthew Smyth; Thomas Jaki; Michael W Beresford Journal: Lancet Rheumatol Date: 2020-02-07